Monsanto will have access to Dow AgroScience’s EXZACT precision technology platform after reaching a licensing agreement this week.

The platform is said to create crop varieties and lines with improved traits faster through a toolkit that allows for genome modification in plants. The technology is based on enzymes called “zinc finger nucleases” that allow researchers to add, delete or edit plant DNA. This technology should help decrease the amount of time and expense it takes to bring improved products to the market.

“Monsanto is pleased to pursue applications of this genome-editing technology for the development of new plant discoveries and solutions for farmers,” says Tom Adams, Ph.D., biotechnology lead for Monsanto. “Zinc finger nucleases are a well-established technology for gene editing and this license, together with our existing and other licensed technology, will allow us to pursue product development while further enabling our growing body of research in this emerging field.”

Dow developed EXZACT technology under an exclusive license and collaboration agreement with Sangamo BioSciences, Inc.

“EXZACT technology is helping to deliver next generation crop improvements into the hands of farmers,” says Daniel R. Kittle, Ph.D., vice president, research and development, Dow AgroSciences. “Broad adoption of EXZACT by industry partners, such as Monsanto, expands access to solutions that will improve grower productivity and profitability.”

Financial and other terms of the agreement have not been disclosed.